Hepatitis B is a viral infection of the liver that many people discover from a lab report rather than from symptoms. That is why the result can feel confusing: the panel comes back with three or four abbreviations, some marked positive and some negative, and the words next to them rarely explain what happens next. This article decodes that panel line by line, shows what the usual result combinations mean, and covers who needs treatment versus monitoring.
In this article you will learn what HBsAg, anti-HBs, anti-HBc, HBeAg and HBV DNA each measure, how to read the pattern they form together, why United States guidance now recommends testing every adult once, and what long-term follow-up looks like for someone living with the chronic form. The tone is practical, not alarming: most people who test positive today live full lives with straightforward follow-up.
What hepatitis B is and how it spreads
The hepatitis B virus targets liver cells. Once inside, it copies itself and the immune system responds by attacking the infected cells. Most of the liver damage comes from that immune response rather than the virus itself, which explains a puzzling fact: someone can carry a large amount of virus and feel well, while someone with less virus has clearly abnormal liver tests.
How the virus is transmitted
The virus travels in blood, semen and other body fluids. In practice that means transmission at birth, sexual contact, shared needles or drug equipment, needlestick injuries, and shared personal items that may carry traces of blood such as razors or glucose lancets. It is not spread by hugging, sharing food, coughing, sneezing or using the same toilet. A different virus, spread mainly through contaminated food and water, causes hepatitis A, and another bloodborne liver virus that is now curable with short courses of tablets causes hepatitis C.
Why age at infection changes everything
Age at infection is the single strongest predictor of what happens next. The Centers for Disease Control and Prevention reports that about 90 percent of infants infected at birth stay chronically infected, along with roughly 30 percent of children infected between one and five. In adults the picture reverses: about 95 percent clear the infection completely and are then immune for life. This is why newborn protection carries so much weight, and why a chronic diagnosis in an adult often traces back to infancy.
Symptoms, and why so many people have none
The acute phase
When symptoms appear, Mayo Clinic notes they usually start one to four months after exposure. They include fatigue, loss of appetite, nausea, abdominal discomfort under the right ribs, joint pain, dark urine, pale stools and jaundice, the yellow tint of skin and eyes. Doctors watching for jaundice check total bilirubin levels, which rise when the liver cannot process this yellow pigment normally. Many adults pass through the acute phase with nothing more than a few tired weeks.
The chronic phase
Chronic hepatitis B is usually silent, sometimes for decades. Symptoms appear only once significant scarring has built up, which is why testing matters more than waiting for a warning sign. The same blood draw that detects the virus usually measures the liver enzyme ALT, and your report will also list the liver enzyme AST. Patterns across several enzymes say more than any single number, which is why it helps to read a guide to high liver enzyme results before drawing conclusions from one line of a report.
When to see a doctor
- Yellowing of the skin or the whites of the eyes, at any age, deserves same-day medical advice.
- A positive result, even with no symptoms at all, should lead to a medical appointment within a few weeks.
- Any known exposure, such as a needlestick, needs advice within 24 hours, because protection given quickly still works.
The hepatitis B blood panel, marker by marker
A hepatitis B evaluation is not one test but a small set of markers, each answering a different question. Read alone, any one of them can mislead. Read together, they tell a clear story.
HBsAg, the surface antigen
HBsAg is a fragment of the outer shell of the virus. Finding it in blood means the virus is present right now and the person can transmit it. A positive HBsAg that is still positive six months later defines a chronic infection.
Anti-HBs, the protective antibody
Anti-HBs is the antibody your immune system builds against that shell, and it is the protective one. It appears after a successful vaccine course, and also after an infection the body cleared. Laboratories report it as a number, and a level at or above 10 milli-international units per milliliter is generally taken as protective.
Anti-HBc, total and IgM
Anti-HBc is the antibody against the inner core of the virus. It carries information no other marker provides: the vaccine never produces it, so anti-HBc positive means the body genuinely met the real virus, whatever the outcome. The IgM subtype is the early version, present mainly in the first six months. That distinction is what separates a recent infection from an old resolved one when HBsAg is positive.
HBeAg and anti-HBe
These are a second antigen and its matching antibody, and they roughly track how actively the virus is replicating. HBeAg positive generally suggests high replication and higher infectiousness, and converting to anti-HBe usually means replication has slowed. The nuance worth knowing is that some viral strains never produce this antigen, so an HBeAg negative result does not rule out active infection on its own.
HBV DNA, the viral load
HBV DNA counts virus particles directly, in international units per milliliter. It is the most precise measure and drives two decisions: whether to start treatment, and whether it is working. During pregnancy it also determines whether the mother needs medication to protect the baby. Unlike the antibody markers, viral load moves over time, so a single value is a snapshot, not a verdict.
Reading your results: what the common combinations mean
Most hepatitis B reports fall into one of six patterns. The table below covers the three markers in the standard screening panel. Find your pattern, then bring the report to your clinician rather than acting on it alone.
| HBsAg | Anti-HBs | Anti-HBc (total) | What this combination usually means |
|---|---|---|---|
| Negative | Negative | Negative | Susceptible. You have never been infected and are not protected. Vaccination is the usual next step. |
| Negative | Positive | Negative | Immune from vaccination. Your body made protective antibodies from the vaccine, never from the virus. |
| Negative | Positive | Positive | Immune from a past infection you cleared, keeping protective antibodies. |
| Positive | Negative | Positive, with IgM positive | Acute infection, usually acquired within the last six months. |
| Positive | Negative | Positive, with IgM negative | Chronic infection. The virus has persisted beyond six months and needs long-term follow-up. |
| Negative | Negative | Positive | Isolated core antibody. Several explanations are possible, so this result needs a repeat test and a clinical review. |
When the pattern looks contradictory
Two situations confuse people regularly. The first is the last row of the table: anti-HBc positive with nothing else. It can reflect a distant infection whose protective antibody has faded, a very low-level infection, or a false positive. The right response is a repeat test and a viral load measurement, not worry.
The second is finding HBsAg and anti-HBs positive together, which the classic rules say should not happen. It is rare and real, and it does not mean the laboratory erred. Recent antibody infusions can also produce temporarily misleading results. In both cases the answer is the same: repeat the panel and add a viral load.
Who should be tested, and when
Testing every adult once
United States guidance changed meaningfully in recent years. The CDC recommends that every adult aged 18 and over be tested at least once in their lifetime, using a triple panel that measures HBsAg, anti-HBs and total anti-HBc together. Risk-based screening kept missing people, because disclosing a risk factor can feel stigmatizing and because many people were infected in infancy and have no risk history to report. The CDC also states that anyone who asks for the test should receive it, without having to explain why.
Groups who need repeat testing
- Every pregnant person, at each pregnancy, regardless of previous results or vaccination status.
- People born in regions where the virus is common, and infants born to parents from those regions.
- Anyone about to start medication that suppresses the immune system, because a dormant infection can reactivate.
The tests that come next after a positive result
A positive HBsAg opens a short assessment rather than an immediate treatment decision. Clinicians add a viral load, HBeAg and anti-HBe, liver enzymes and markers of liver function. They track albumin blood levels, watch the platelet count, which falls as scarring advances, and often include the international normalized ratio, which gauges how well the liver makes clotting proteins. An ultrasound and a liver stiffness measurement complete the picture.
Treatment: who is treated and who is monitored
Treatable, but usually not curable
This is the honest headline, and it differs sharply from hepatitis C. Current medications suppress the virus extremely well but rarely eliminate it, because it stores a stable copy of its genetic material inside liver cell nuclei that today’s drugs cannot reach. What treatment achieves is still worth a great deal: an undetectable viral load, normal liver enzymes, halted or partly reversed scarring, and a lower risk of liver cancer. Specialists call the best realistic outcome a functional cure, where the surface antigen disappears and stays away, which happens in a minority of treated people.
Who starts antiviral treatment
Treatment decisions in hepatitis B rest on viral load, liver enzymes and the degree of scarring, not on a positive test alone. In broad terms, medication is recommended for a high viral load with persistently raised liver enzymes, for anyone with cirrhosis, for people starting immune-suppressing therapy, and for pregnant people with a high viral load. The usual medications are daily tablets from the tenofovir and entecavir families, generally well tolerated and taken long term.
Who is monitored instead
Many people with chronic hepatitis B have a low viral load and normal liver enzymes. For them, treatment adds side effects and cost without clear benefit, so the plan is structured monitoring: liver enzymes and viral load every six to twelve months, plus periodic assessment of liver stiffness. Monitoring is not doing nothing. It is watching for the moment when treatment would start to help, and that moment may arrive years later or never.
Liver cancer surveillance
The chronic form raises the risk of primary liver cancer even without cirrhosis, which is not true of most other liver diseases. For that reason, adults in higher-risk groups are offered an abdominal ultrasound every six months, sometimes paired with the alpha-fetoprotein blood test. The goal is to detect early primary liver cancer, while it is small and treatable. The same schedule applies to anyone who has developed liver cirrhosis.
Prevention: vaccination and protecting newborns
The hepatitis B vaccine
It is one of the most effective vaccines in routine use. It contains no live virus, only the surface protein, which is why it produces anti-HBs but never anti-HBc. Adult schedules involve two or three doses depending on the product. A titer test one to two months after the last dose confirms protection, and non-responders can be revaccinated. Once a protective level is reached, protection appears to last decades even if the measured antibody level later drifts down.
Preventing transmission from parent to newborn
This is where prevention has the largest effect, because infection at birth so often becomes lifelong. The approach combines three elements: testing every pregnant person for HBsAg, giving the newborn both the first vaccine dose and hepatitis B immune globulin within 12 hours of birth, and adding antiviral medication in the third trimester when the mother’s viral load is high. These steps prevent the great majority of transmissions, and breastfeeding remains possible.
Everyday precautions for households
Family members and partners should be tested and vaccinated. Otherwise ordinary life continues unchanged: do not share razors, toothbrushes or glucose lancets, cover open cuts, and tell any healthcare or dental provider about the diagnosis. Alcohol deserves attention, since it accelerates scarring in an already stressed liver.
Latest scientific advances
Research from the last three years has been less about new cures than about doing the basics better. Here is what it suggests, in plain terms.
Half of at-risk people miss their liver cancer scans
A 2025 pooled analysis of 48 studies and more than a million people found that only about half of those who should receive six-monthly liver ultrasounds actually get them. This was a meta-analysis, meaning researchers pooled many separate studies to get a more reliable overall picture. What this means for you: surveillance is proven to help but often falls through the cracks. If you live with the chronic form, ask at your next visit when your ultrasound is due.
A painless stiffness scan helps predict risk
A 2024 review of ten studies found that liver stiffness measured by elastography, a quick painless scan that gauges how firm the liver feels, helps identify who is more likely to develop liver cancer among people with the chronic form, with stiffer livers carrying higher risk. What this means for you: if your clinic offers this scan, it adds information blood tests alone cannot give, and it takes minutes with no needle involved.
Both forms of tenofovir protect babies during pregnancy
A 2024 review pooling 31 studies of mothers with a high viral load found that tenofovir given in late pregnancy, in either of its two forms, sharply reduced transmission to infants when combined with standard newborn immunization, with a reassuring safety profile. What this means for you: if you are pregnant with a high viral load, this combined approach is well supported, and the choice between the two tenofovir forms can be discussed with your specialist.
One extra test that most people with hepatitis B never get
Hepatitis D only infects people who already carry the virus, and it makes liver disease more serious. A 2025 United States modeling study estimated that only about one in eight adults with the chronic form has ever been tested for it, and concluded that testing everyone once would be worth the cost. What this means for you: if you have never had a hepatitis D test, it is a fair question to raise with your doctor.
Unusual marker combinations are real, not laboratory errors
A 2026 case report described a woman with a chronic infection whose blood carried both the surface antigen and the protective surface antibody at once, a combination the standard rules say should not occur. A case report describes a single patient, so it shows that something can happen rather than how often it does. What this means for you: if your results look self-contradictory, the usual next step is a repeat test with a viral load rather than assuming a mix-up.
Glossary
| Term | Definition |
|---|---|
| HBsAg (hepatitis B surface antigen) | A piece of the virus shell found in blood. Its presence means the virus is currently there and the person can pass it on. |
| Anti-HBs (surface antibody) | A protective antibody your immune system makes against the virus shell. It comes either from the vaccine or from an infection you cleared. |
| Anti-HBc (core antibody) | An antibody against the inner part of the virus. It shows the body actually met the real virus at some point. The vaccine never produces it. |
| IgM anti-HBc | An early type of core antibody. It appears in the first months of an infection, so it helps separate a recent infection from an old one. |
| HBeAg and anti-HBe | A second antigen and its matching antibody. Together they give a rough idea of how actively the virus is copying itself. |
| HBV DNA (viral load) | A count of virus particles in the blood. It is the most direct measure of how much virus is present and how it responds to treatment. |
| Acute infection | A recent infection, present for less than six months. Most healthy adults clear it on their own. |
| Chronic infection | An infection that lasts beyond six months. It is manageable with monitoring and, when needed, daily medication. |
| Cirrhosis | Advanced scarring that replaces working liver tissue. It builds up slowly over years of inflammation. |
| Hepatocellular carcinoma | The most common type of primary liver cancer. Regular scans are used in higher-risk people to catch it early. |
Frequently asked questions
Is hepatitis B curable?
Chronic hepatitis B is treatable but, in most cases, not curable in the way hepatitis C is. Antiviral tablets suppress the virus so effectively that the viral load becomes undetectable, liver inflammation settles and the risk of complications drops substantially. What they cannot reliably do is clear a stable copy of viral genetic material that sits inside liver cells. A minority of treated people do reach what specialists call a functional cure, where the surface antigen disappears for good. Acute hepatitis B is different: about 95 percent of healthy adults clear it without any treatment at all.
Is hepatitis B contagious through everyday contact?
No. The virus does not spread through hugging, kissing, sharing meals or cutlery, coughing, sneezing, swimming pools or toilet seats. It requires contact with infected blood or body fluids, which in practice means birth, sexual contact, shared needles or drug equipment, or shared items that can carry traces of blood such as razors and lancets. Vaccinated household members and partners are protected, which is why testing and vaccinating the people you live with is the standard recommendation after a diagnosis.
Can a positive hepatitis B test ever become negative?
Sometimes, and the answer depends on which test turned positive. A positive surface antigen in the acute phase usually becomes negative within six months in adults, as the immune system clears the infection. In chronic infection, spontaneous loss of the surface antigen also happens, but slowly and in a small percentage of people each year, and antiviral treatment modestly increases that chance. The core antibody, by contrast, generally stays positive for life. It is a permanent record that the body met the virus, and it does not mean you are still infectious.
What does my hepatitis B titer number mean?
A titer usually refers to the anti-HBs level, the protective antibody. Laboratories report it in milli-international units per milliliter, and a value at or above 10 is generally read as protective. Below that, a healthcare provider may recommend another vaccine dose or a full repeat series, then a retest one to two months later. A titer that has fallen below 10 years after a documented good response is a different situation from never having responded, so bring your vaccination history to the appointment.
Is hepatitis B dangerous during pregnancy?
Hepatitis B rarely harms the pregnancy itself. The concern is transmission to the baby at birth, which without preventive measures leads to chronic infection in most exposed newborns. That is why every pregnant person is tested at every pregnancy. When the result is positive, the viral load guides whether antiviral medication is added in the third trimester, and the newborn receives both the vaccine and hepatitis B immune globulin within 12 hours of delivery. With these steps in place, transmission becomes uncommon and breastfeeding remains possible.
Should I get vaccinated if I have already had hepatitis B?
If you cleared a past infection and have protective surface antibodies, vaccination adds nothing, because you already carry the immunity the vaccine is designed to create. If you currently have a chronic infection, the vaccine cannot help either, since it prevents infection rather than treating one. Vaccination against hepatitis A, however, is often recommended in both situations, to spare a liver that is already under strain from a second viral infection. Your specific panel result determines which of these applies to you.
Sources
- Centers for Disease Control and Prevention — Clinical Testing and Diagnosis for Hepatitis B, 2025 — cdc.gov
- MedlinePlus, National Library of Medicine — Hepatitis B, 2025 — medlineplus.gov
- Mayo Clinic — Hepatitis B: Symptoms and causes, 2025 — mayoclinic.org
- Tang NSY, Gunalan S, Ong CEY, et al. — Meta-Analysis: Utilisation of Hepatocellular Carcinoma Surveillance — Alimentary Pharmacology and Therapeutics, 2025 — doi.org/10.1111/apt.70403
- Jin YJ, Kim HY, Suh YJ, et al. — Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: systematic review and meta-analysis — Clinical and Molecular Hepatology, 2024 — doi.org/10.3350/cmh.2024.0163
- Pan CQ, Zhu L, Yu AS, et al. — Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Preventing Vertical Transmission in Chronic Hepatitis B Mothers: A Systematic Review and Meta-Analysis — Clinical Infectious Diseases, 2024 — doi.org/10.1093/cid/ciae288
- Toy M, Hutton D, Teshale E, et al. — Cost-Effectiveness of One-time Universal Testing for Hepatitis D Among Adults With Chronic Hepatitis B in the United States — Clinical Infectious Diseases, 2025 — doi.org/10.1093/cid/ciaf181
- Balah GM, Bazuqamah MS, Helal EA, et al. — Breaking the serologic rule: chronic hepatitis B with simultaneous HBsAg and anti-HBs positivity, a case report — Journal of Medical Case Reports, 2026 — doi.org/10.1186/s13256-026-06091-y
Further reading
- Start by reading a patient guide to reading lab results
- Learn how clinicians interpret prothrombin time test results
- Find out what raises alkaline phosphatase blood levels
- Understand why a urine strip can detect bilirubin in a urine sample
- Read what to make of abnormal blood test results when you feel fine
Understand your lab results with BloodSense
A hepatitis B panel is one of the clearest examples of a report that only makes sense when the markers are read together rather than one line at a time. BloodSense reads your uploaded results in context and explains in plain language what a surface antigen, a surface antibody, a core antibody, a viral load or a liver enzyme value is telling you, and which questions are worth raising at your next appointment. It helps you understand your results; it does not diagnose, and it does not replace your doctor.
